Sermorelin vs tesamorelin

At a glance

Evidence grade

Where a compliant provider sells this today

The short answer

Sermorelin and tesamorelin are both analogues of growth-hormone-releasing hormone, and both act on the same receptor. The difference that matters is what each one has been tested for.

Tesamorelin was tested in controlled trials against a defined clinical outcome in a defined population, and it reached FDA approval on that basis. Sermorelin has an older approval history built around pituitary testing and around children with a growth hormone deficiency.

Neither of those bodies of work asked what the compound does for a healthy adult who wants to feel younger. That is the use both are marketed for now, and on that question the two files are much closer than the approval status suggests.

What each molecule is

Sermorelin is the shortest fragment of growth-hormone-releasing hormone that still carries the activity of the whole molecule. Its design is subtractive: keep the active piece, drop the rest.

Tesamorelin takes a different approach. It is a stabilized analogue of the same hormone, modified so it survives longer against the enzymes that break the natural signal down quickly.

Both leave the pituitary gland in charge. Both work one step upstream of growth hormone itself, so the release they trigger still passes through the body’s own braking signals. That shared property is the reason they are discussed together at all.

What tesamorelin was actually approved for

Tesamorelin holds an FDA approval for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is a specific problem in a specific population, and the approval is scoped to it.

It got there the ordinary way: controlled trials, a defined clinical outcome, measured in the people the drug was meant to help. That is the whole reason its file looks different from every other compound in this class.

The approval is worth taking seriously and it is worth reading narrowly. An approval certifies that a drug did a particular thing, in particular people, well enough for a regulator. It does not certify the molecule in general, and it does not travel to a different population with a different goal.

Why the approval does not settle the comparison buyers are making

Most people comparing these two are not asking about lipodystrophy. They are asking which one will change how their body looks and how they feel.

On that question, tesamorelin’s trial base is being borrowed rather than applied. A person without the approved indication, buying tesamorelin for general body composition or for aging, is outside the population the evidence describes. The molecule is the same; the question is not.

This is where the approval gets used as a credential. A vendor can truthfully say tesamorelin is FDA-approved, and a reader can hear it as "this one is proven." Those are different statements, and the distance between them is the whole subject here.

What sermorelin brings, and what it does not

Sermorelin provokes a growth hormone response. That is not a claim needing defense — it is the property an approved diagnostic product was built on. A test asking whether a pituitary gland can respond only works if the agent reliably makes a working gland respond.

Growth hormone then drives the liver to produce insulin-like growth factor 1, and IGF-1 is the marker most clinics use to say a course is working. When a clinic reports that the numbers moved, the numbers plausibly did move.

A hormone level is not an outcome. It is a proxy for one, and it earns its status as a proxy only when somebody has shown that moving it moves the thing being sold. For sermorelin in adults, that work has not been published.

What tesamorelin proves about the class

Tesamorelin is useful in this comparison for a reason that has nothing to do with buying it. It makes the shape of the missing evidence concrete.

Nobody has to speculate about what a convincing trial of sermorelin would look like, because a molecule in the same class has already had one. A defined population, a placebo comparison, an outcome a person would recognize, and enough duration for the effect to be real rather than temporary.

The bar is reachable for growth-hormone-releasing hormone analogues. It has been cleared once, for one indication. It has not been cleared for either compound in the adult wellness market where both are now sold.

Where the regulatory question sits

Sermorelin is not currently marketed in the United States as an FDA-approved product, so what is sold here is compounded. Tesamorelin holds an FDA approval for its defined indication, and whether and how it may be compounded is a separate question that is unsettled. No outcome, timeline or likelihood is characterized here.

Positions like these change on their own schedule, and a summary written into a comparison drifts out of date the moment the record moves. Each compound’s status page carries the dated record, and that is where the current position is stated.

The practically useful part is what compounded means. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, whatever an individual pharmacy’s own standards are. That is a statement about the review pathway, not an allegation about any pharmacy.

How the grades were set

Both compounds are graded limited evidence on this page, and for tesamorelin the grade covers the longevity and wellness use it is marketed for here. It is not a grade on the approved indication, which rests on its own controlled trial base and would be read differently.

That distinction is the point of grading the marketed use rather than the label. A reader deciding whether to buy tesamorelin from a wellness clinic is not buying the indication. Grading the label would tell them something true about a population they are not in.

Sermorelin is graded limited for the ordinary reason: a real, mechanistically well-supported effect on a hormone axis, with thin long-term outcome data for the uses it is sold for. Either grade moves when randomized placebo-controlled trials appear in the population actually buying the product.